MarketPulse

drug delivery technology

2 articles
The Motley FoolThe Motley Fool··Motley Fool Youtube

Novo Nordisk Stock Looks Cheap, But Execution Risks Cloud Recovery Outlook

Novo Nordisk stock trades cheap but faces execution headwinds versus Eli Lilly's superior operational performance in the booming GLP-1 market.
LLYNVOweight loss drugspharmaceutical competition
BenzingaBenzinga··Prnewswire

Orexo Charts New Course with R&D Day Showcase of AmorphOX Pipeline

Orexo invites investors to March 24 R&D Day in Stockholm to present post-Zubsolv strategy, featuring AmorphOX technology and pipeline programs OX640 and OX390.
ORXOYpipelinestrategic priorities